Remdesivir granted early access in the UK by MHRA for COVID-19 treatment.- Gilead Sciences

Remdesivir has been granted a special early access status in the UK, which will allow patients hospitalized with COVID-19 to receive the antiviral treatment.The public assessment report issued by the Medicines and Healthcare products Regulatory Agency (MHRA) cites trial data which shows remdesivir reduced the time of recovery from 15 days to 11 days in patients with severe COVID-19 These data are the same data from an NIH-led study which led the FDA to grant remdesivir emergency use approval (EUA) on 2 May.

A new study published in the New England Journal of Medicine (NEJM) on 22 May 2020 added to these data, confirming some of earlier trial’s signs of benefits, but showing no benefits for the most critically ill and intubated patients.